Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Titel:
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Auteur:
Wu, Yi-Long Guarneri, Valentina Voon, Pei Jye Lim, Boon Khaw Yang, Jin-Ji Wislez, Marie Huang, Cheng Liam, Chong Kin Mazieres, Julien Tho, Lye Mun Hayashi, Hidetoshi Nhung, Nguyen Viet Chia, Puey Ling de Marinis, Filippo Raskin, Jo Zhou, Qinghua Finocchiaro, Giovanna Le, Anh Tuan Wang, Jialei Dooms, Christophe Kato, Terufumi Nadal, Ernest Hin, How Soon Smit, Egbert F Wermke, Martin Tan, Daniel Morise, Masahiro O'Brate, Aurora Adrian, Svenja Pfeiffer, Boris M Stroh, Christopher Juraeva, Dilafruz Strotmann, Rainer Goteti, Kosalaram Berghoff, Karin Ellers-Lenz, Barbara Karachaliou, Niki Le, Xiuning Kim, Tae Min